272 related articles for article (PubMed ID: 19500514)
1. [Insulin treatment in children].
Birkebaek NH; Hertz B; Olsen BS
Ugeskr Laeger; 2009 Jun; 171(23):1919-22. PubMed ID: 19500514
[TBL] [Abstract][Full Text] [Related]
2. Clinical strategies for controlling peaks and valleys: type 1 diabetes.
Bolli GB
Int J Clin Pract Suppl; 2002 Jul; (129):65-74. PubMed ID: 12166610
[TBL] [Abstract][Full Text] [Related]
3. Type 1 diabetes control and pregnancy outcomes in women treated with continuous subcutaneous insulin infusion (CSII) or with insulin glargine and multiple daily injections of rapid-acting insulin analogues (glargine-MDI).
Bruttomesso D; Bonomo M; Costa S; Dal Pos M; Di Cianni G; Pellicano F; Vitacolonna E; Dodesini AR; Tonutti L; Lapolla A; Di Benedetto A; Torlone E;
Diabetes Metab; 2011 Nov; 37(5):426-31. PubMed ID: 21474360
[TBL] [Abstract][Full Text] [Related]
4. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir.
Peterson GE
Curr Med Res Opin; 2006 Dec; 22(12):2613-9. PubMed ID: 17166343
[TBL] [Abstract][Full Text] [Related]
5. Benefits of continuous subcutaneous insulin infusion in type 1 diabetes previously treated with multiple daily injections with once-daily glargine and pre-meal analogues.
Torres I; Ortego J; Valencia I; García-Palacios MV; Aguilar-Diosdado M
Exp Clin Endocrinol Diabetes; 2009 Sep; 117(8):378-85. PubMed ID: 19629931
[TBL] [Abstract][Full Text] [Related]
6. [The use of continuous subcutaneous insulin infusion (CSII) with personal insulin pumps in the treatment of children and adolescents with diabetes type 1].
Jarosz-Chobot P
Wiad Lek; 2004; 57(5-6):263-6. PubMed ID: 15518073
[TBL] [Abstract][Full Text] [Related]
7. Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes.
Bott S; Tusek C; Jacobsen LV; Endahl L; Draeger E; Kapitza C; Heise T
Diabet Med; 2006 May; 23(5):522-8. PubMed ID: 16681561
[TBL] [Abstract][Full Text] [Related]
8. Rationale for using combinations of short-acting insulin analogue and NPH insulin at mealtime in the treatment of type 1 diabetes mellitus.
Bolli GB
J Pediatr Endocrinol Metab; 1999; 12 Suppl 3():737-44. PubMed ID: 10626264
[No Abstract] [Full Text] [Related]
9. Quality of life and treatment satisfaction in adults with Type 1 diabetes: a comparison between continuous subcutaneous insulin infusion and multiple daily injections.
; Nicolucci A; Maione A; Franciosi M; Amoretti R; Busetto E; Capani F; Bruttomesso D; Di Bartolo P; Girelli A; Leonetti F; Morviducci L; Ponzi P; Vitacolonna E
Diabet Med; 2008 Feb; 25(2):213-20. PubMed ID: 18201210
[TBL] [Abstract][Full Text] [Related]
10. Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion.
Pickup JC; Sutton AJ
Diabet Med; 2008 Jul; 25(7):765-74. PubMed ID: 18644063
[TBL] [Abstract][Full Text] [Related]
11. Continuous subcutaneous insulin infusion benefits quality of life in preschool-age children with type 1 diabetes mellitus.
Opipari-Arrigan L; Fredericks EM; Burkhart N; Dale L; Hodge M; Foster C
Pediatr Diabetes; 2007 Dec; 8(6):377-83. PubMed ID: 18036064
[TBL] [Abstract][Full Text] [Related]
12. Why pumps? Continuous subcutaneous insulin infusion for children and adolescents with type 1 diabetes.
Weintrob N; Shalitin S; Phillip M
Isr Med Assoc J; 2004 May; 6(5):271-5. PubMed ID: 15151365
[TBL] [Abstract][Full Text] [Related]
13. Flexibility of rapid-acting insulin analogues in children and adolescents with diabetes mellitus.
Danne T
Clin Ther; 2007; 29 Suppl D():S145-52. PubMed ID: 18191066
[TBL] [Abstract][Full Text] [Related]
14. Continuous subcutaneous insulin infusion (CSII) 30 years later: still the best option for insulin therapy.
Bruttomesso D; Costa S; Baritussio A
Diabetes Metab Res Rev; 2009 Feb; 25(2):99-111. PubMed ID: 19172576
[TBL] [Abstract][Full Text] [Related]
15. Rational use of insulin analogues in the treatment of type 1 diabetes mellitus.
Bolli GB
Pediatr Endocrinol Rev; 2003 Sep; 1(1):9-21. PubMed ID: 16437009
[TBL] [Abstract][Full Text] [Related]
16. Selecting an insulin program for type 1 diabetes.
Scheiner G
Diabetes Self Manag; 2003; 20(5):54-6, 58. PubMed ID: 14679953
[No Abstract] [Full Text] [Related]
17. Pediatric quality of life in transitioning to the insulin pump: does prior regimen make a difference?
Cogen FR; Henderson C; Hansen JA; Streisand R
Clin Pediatr (Phila); 2007 Nov; 46(9):777-9. PubMed ID: 17585009
[TBL] [Abstract][Full Text] [Related]
18. Type I diabetes and insulin therapy.
Hirsch IB; Farkas-Hirsch R
Nurs Clin North Am; 1993 Mar; 28(1):9-23. PubMed ID: 8451220
[TBL] [Abstract][Full Text] [Related]
19. Benefits of a bolus calculator in pre- and postprandial glycaemic control and meal flexibility of paediatric patients using continuous subcutaneous insulin infusion (CSII).
Shashaj B; Busetto E; Sulli N
Diabet Med; 2008 Sep; 25(9):1036-42. PubMed ID: 18937673
[TBL] [Abstract][Full Text] [Related]
20. Twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn therapy for newly diagnosed type 1 diabetes.
Al Shamsi AM
Pediatrics; 2008 Sep; 122(3):675-6; author reply 676. PubMed ID: 18762540
[No Abstract] [Full Text] [Related]
[Next] [New Search]
